CCND3 is indispensable for the maintenance of B-cell acute lymphoblastic leukemia.
Journal
Oncogenesis
ISSN: 2157-9024
Titre abrégé: Oncogenesis
Pays: United States
ID NLM: 101580004
Informations de publication
Date de publication:
10 Jan 2022
10 Jan 2022
Historique:
received:
06
07
2021
accepted:
22
12
2021
revised:
08
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
12
1
2022
Statut:
epublish
Résumé
The D-type cyclins (CCND1, CCND2, and CCND3) in association with CDK4/6 are known drivers of cell cycle progression. We reported previously that inactivation of FOXO1 confers growth arrest and apoptosis in B-ALL, partially mediated by subsequent depletion of CCND3. Given that previously the canonical MYC target CCND2 has been considered to play the major role in B-ALL proliferation, further investigation of the role of FOXO1 in CCND3 transcription and the role of CCND3 in B-ALL is warranted. In this study, we demonstrated that CCND3 is essential for the proliferation and survival of B-ALL, independent of the mutational background. Respectively, its expression at mRNA level exceeds that of CCND1 and CCND2. Furthermore, we identified FOXO1 as a CCND3-activating transcription factor in B-ALL. By comparing the effects of CCND3 depletion and CDK4/6 inhibition by palbociclib on B-ALL cells harboring different driver mutations, we found that the anti-apoptotic effect of CCND3 is independent of the kinase activity of the CCND3-CDK4/6 complex. Moreover, we found that CCND3 contributes to CDK8 transcription, which in part might explain the anti-apoptotic effect of CCND3. Finally, we found that increased CCND3 expression is associated with the development of resistance to palbociclib. We conclude that CCND3 plays an essential role in the maintenance of B-ALL, regardless of the underlying driver mutation. Moreover, downregulation of CCND3 expression might be superior to inhibition of CDK4/6 kinase activity in terms of B-ALL treatment.
Identifiants
pubmed: 35013097
doi: 10.1038/s41389-021-00377-0
pii: 10.1038/s41389-021-00377-0
pmc: PMC8748974
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1Subventions
Organisme : NIAID NIH HHS
ID : R01 AI164692
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA157644
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA213138
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197628
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Bethesda M. SEER Cancer Statistics Review, 1973–2013 SEER Cancer Statistics. National Cancer Institute. 2016. https://seer.cancer.gov/archive/csr/1975_2011/results_single/sect_28_table.03.pdf%0A , https://seer.cancer.gov/archive/csr/1975_2013/%0A , http://seer.cancer.gov/csr/1973_1996/ .
Rowe JM. Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol. 2010;150:389–405. https://doi.org/10.1111/j.1365-2141.2010.08246.x .
doi: 10.1111/j.1365-2141.2010.08246.x
pubmed: 20573154
Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P. et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and leukemia group B study 8811. Blood. 1995;85:2025–37.
pubmed: 7718875
doi: 10.1182/blood.V85.8.2025.bloodjournal8582025
Mohseni M, Uludag H, Brandwein JM. Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications. Am J Blood Res. 2018;8:29–56.
pubmed: 30697448
pmcid: 6334189
Wang F, Demir S, Gehringer F, Osswald CD, Seyfried F, Enzenmüller S. et al. Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:2929–42.
pubmed: 29622548
doi: 10.1182/blood-2017-10-813576
Köhrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, et al. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia. 2016;30:1246–54. https://doi.org/10.1038/leu.2016.9 .
doi: 10.1038/leu.2016.9
pubmed: 26847027
pmcid: 5459356
Abdelrasoul H, Vadakumchery A, Werner M, Lenk L, Khadour A, Young M, et al. Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Nat Commun. 2020;11:3194. https://doi.org/10.1038/s41467-020-16927-w .
doi: 10.1038/s41467-020-16927-w
pubmed: 32581241
pmcid: 7314847
Dimova DK, Dyson NJ. The E2F transcriptional network: Old acquaintances with new faces. Oncogene. 2005;24:2810–26.
pubmed: 15838517
doi: 10.1038/sj.onc.1208612
Cooper AB, Sawai CM, Sicinska E, Powers SE, Sicinski P, Clark MR, et al. A unique function for cyclin D3 in early B cell development. Nat Immunol. 2006;7:489–97. https://doi.org/10.1038/ni1324 .
doi: 10.1038/ni1324
pubmed: 16582912
Cato MH, Chintalapati SK, Yau IW, Omori SA, Rickert RC. Cyclin D3 is selectively required for proliferative expansion of germinal center B cells. Mol Cell Biol. 2011;31:127–37.
pubmed: 20956554
doi: 10.1128/MCB.00650-10
Sicinska E, Aifantis I, Le Cam L, Swat W, Borowski C, Yu Q, et al. Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell. 2003;4:451–61.
pubmed: 14706337
doi: 10.1016/S1535-6108(03)00301-5
Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell. 2012;22:438–51.
pubmed: 23079655
pmcid: 3487466
doi: 10.1016/j.ccr.2012.09.015
Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999;18:5321–33.
pubmed: 10508165
pmcid: 1171602
doi: 10.1093/emboj/18.19.5321
Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, et al. Self-enforcing feedback activation between BCL6 and Pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 2015;27:409–25. https://doi.org/10.1016/j.ccell.2015.02.003 .
doi: 10.1016/j.ccell.2015.02.003
pubmed: 25759025
pmcid: 4618684
Kode A, Mosialou I, Silva BC, Rached MT, Zhou B, Wang J, et al. FOXO1 orchestrates the bone-suppressing function of gut-derived serotonin. J Clin Invest. 2012;122:3490–503.
pubmed: 22945629
pmcid: 3461930
doi: 10.1172/JCI64906
Zhang T, Kim DH, Xiao X, Lee S, Gong Z, Muzumdar R, et al. Foxo1 plays an important role in regulating β-cell compensation for insulin resistance in male mice. Endocrinology. 2016;157:1055–70.
pubmed: 26727107
pmcid: 4769368
doi: 10.1210/en.2015-1852
Coller HA, Forman JJ, Legesse-Miller A. “Myc’ed messages”: Myc induces transcription of E2F1 while inhibiting its translation via a microRNA polycistron. PLoS Genet Public Libr Sci. 2007;3:1319–24.
Ma Y, Yuan J, Huang M, Jove R, Cress WD. Regulation of the cyclin D3 promoter by E2F1. J Biol Chem. 2003;278:16770–6.
pubmed: 12611887
doi: 10.1074/jbc.M212702200
Shin DJ, Joshi P, Hong SH, Mosure K, Shin DG, Osborne TF. Genome-wide analysis of FoxO1 binding in hepatic chromatin: Potential involvement of FoxO1 in linking retinoid signaling to hepatic gluconeogenesis. Nucleic Acids Res. 2012;40:11499–509.
pubmed: 23066095
pmcid: 3526316
doi: 10.1093/nar/gks932
Vogel MJ, Xie L, Guan H, Tooze RM, Maier T, Kostezka U, et al. FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma. Blood. 2014;124:3118–29.
pubmed: 25232062
doi: 10.1182/blood-2014-07-590570
Drexler HG, Macleod RA. History of leukemia-lymphoma cell lines. Hum Cell. 2010;23:75–82.
pubmed: 20973832
doi: 10.1111/j.1749-0774.2010.00087.x
Stong RC, Korsmeyer SJ, Parkin JL, Arthur DC, Kersey JH. Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood. 1985;65:21–31.
pubmed: 3917311
doi: 10.1182/blood.V65.1.21.21
Chan LN, Murakami MA, Robinson ME, Caeser R, Sadras T, Lee J, et al. Signalling input from divergent pathways subverts B cell transformation. Nature. 2020;583:845–51. https://doi.org/10.1038/s41586-020-2513-4 .
doi: 10.1038/s41586-020-2513-4
pubmed: 32699415
pmcid: 7394729
Wang H, Nicolay BN, Chick JM, Gao X, Geng Y, Ren H, et al. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. Nature. 2017;546:426–30.
pubmed: 28607489
pmcid: 5516959
doi: 10.1038/nature22797
Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490:116–20.
pubmed: 22885699
pmcid: 3609867
doi: 10.1038/nature11378
Tamura K, Mukai H, Naito Y, Yonemori K, Kodaira M, Tanabe Y, et al. Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. Cancer Sci. 2016;107:755–63.
pubmed: 26991823
pmcid: 4968608
doi: 10.1111/cas.12932
Lanfray D, Caron A, Roy MC, Laplante M, Morin F, Leprince J, et al. Involvement of the Acyl-CoA binding domain containing 7 in the control of food intake and energy expenditure in mice. Elife. 2016;5:e11742.
pubmed: 26880548
pmcid: 4821795
doi: 10.7554/eLife.11742
Kelly TN, Li C, Hixson JE, Gu D, Rao DC, Huang J, et al. Resequencing study identifies rare renin-angiotensin-aldosterone system variants associated with blood pressure salt-sensitivity: The gensalt study. Am J Hypertens. 2017;30:495–501.
pubmed: 28199472
pmcid: 5861585
doi: 10.1093/ajh/hpx004
Wasik AA, Polianskyte-Prause Z, Dong M-Q, Shaw AS, Yates JR, Farquhar MG, et al. Septin 7 forms a complex with CD2AP and nephrin and regulates glucose transporter trafficking. Mol Biol Cell. 2012;23:3370–9.
pubmed: 22809625
pmcid: 3431928
doi: 10.1091/mbc.e11-12-1010
Wonsey DR, Zeller KI, Dang CV. The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc Natl Acad Sci USA. 2002;99:6649–54.
pubmed: 12011429
pmcid: 124457
doi: 10.1073/pnas.102523299
Liu L, Chen S, Yu M, Ge C, Ren M, Liu B, et al. Deacetylation of HSD17B10 by SIRT3 regulates cell growth and cell resistance under oxidative and starvation stresses. Cell Death Dis. 2020;11:1–14. https://doi.org/10.1038/s41419-020-02763-9 .
doi: 10.1038/s41419-020-02763-9
Zhou L, Wang Z, Xu X, Wan Y, Qu K, Fan H, et al. Nek7 is overexpressed in hepatocellular carcinoma and promotes hepatocellular carcinoma cell proliferation in vitro and in vivo. Oncotarget. 2016;7:18620–30.
pubmed: 26921196
pmcid: 4951314
doi: 10.18632/oncotarget.7620
Raza A, Pandey MS, Jin Q, Mulder KM. km23-1/DYNLRB1 regulation of MEK/ERK signaling and R-Ras in invasive human colorectal cancer cells. Cell Biol Int. 2020;44:155–65.
doi: 10.1002/cbin.11215
Xu J, Zhu Y, Wang F, Zhou Y, Xia G, Xu W. ICMT contributes to hepatocellular carcinoma growth, survival, migration and chemoresistance via multiple oncogenic pathways. Biochem Biophys Res Commun. 2019;518:584–9.
pubmed: 31451223
doi: 10.1016/j.bbrc.2019.08.094
Faber ZJ, Chen X, Gedman AL, Boggs K, Cheng J, Ma J, et al. The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet. 2016;48:1551–6.
pubmed: 27798625
pmcid: 5508996
doi: 10.1038/ng.3709
Zhang C, Lian H, Xie L, Yin N, Cui Y. LncRNA ELFN1-AS1 promotes esophageal cancer progression by up-regulating GFPT1 via sponging miR-183-3p. Biol Chem. 2020;401:1053–61.
pubmed: 32229685
doi: 10.1515/hsz-2019-0430
Menzl I, Zhang T, Berger-Becvar A, Grausenburger R, Heller G, Prchal-Murphy M, et al. A kinase-independent role for CDK8 in BCR-ABL1+ leukemia. Nat Commun. 2019;10:4741. https://doi.org/10.1038/s41467-019-12656-x .
doi: 10.1038/s41467-019-12656-x
pubmed: 31628323
pmcid: 6802219
Buchner M, Müschen M. Targeting the B-cell receptor signaling pathway in B lymphoid malignancies. Curr Opin Hematol. 2014;21:341–9.
pubmed: 24811161
pmcid: 4136419
doi: 10.1097/MOH.0000000000000048
De Dominici M, Porazzi P, Xiao Y, Chao A, Tang HY, Kumar G, et al. Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs. Blood. 2020;135:1560–73.
pubmed: 32040545
pmcid: 7193186
doi: 10.1182/blood.2019003604
Hydbring P, Malumbres M, Sicinski P. Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nat Rev Mol Cell Biol. 2016;17:280–92. https://doi.org/10.1038/nrm.2016.27 .
doi: 10.1038/nrm.2016.27
pubmed: 27033256
pmcid: 4841706
Powers SE, Mandal M, Matsuda S, Miletic AV, Cato MH, Tanaka A, et al. Subnuclear cyclin D3 compartments and the coordinated regulation of proliferation and immunoglobulin variable gene repression. J Exp Med. 2012;209:2199–213.
pubmed: 23109711
pmcid: 3501354
doi: 10.1084/jem.20120800
Karki S, Kennedy DE, Mclean K, Grzybowski AT, Maienschein-Cline M, Banerjee S, et al. Regulated capture of Vκ gene topologically associating domains by transcription factories. Cell Rep. 2018;24:2443–56.
pubmed: 30157436
pmcid: 6310487
doi: 10.1016/j.celrep.2018.07.091
Olshavsky NA, Groh EM, Comstock CES, Morey LM, Wang Y, Revelo MP, et al. Cyclin D3 action in androgen receptor regulation and prostate cancer. Oncogene. 2008;27:3111–21.
pubmed: 18084330
doi: 10.1038/sj.onc.1210981
Peterson LF, Boyapati A, Ranganathan V, Iwama A, Tenen DG, Tsai S, et al. The hematopoietic transcription factor AML1(RUNX1) is negatively regulated by the cell cycle protein cyclin D3. Mol Cell Biol. 2005;25:10205–19.
pubmed: 16287839
pmcid: 1291252
doi: 10.1128/MCB.25.23.10205-10219.2005
Paternot S, Colleoni B, Bisteau X, Roger PP. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes. Cell Cycle. 2014;13:2879–88.
pubmed: 25486476
pmcid: 4615110
doi: 10.4161/15384101.2014.946841
Haines E, Chen T, Kommajosyula N, Chen Z, Herter-Sprie GS, Cornell L, et al. Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer. Oncotarget. 2018;9:31572–89.
pubmed: 30167080
pmcid: 6114982
doi: 10.18632/oncotarget.25803
Pridans C, Holmes ML, Polli M, Wettenhall JM, Dakic A, Corcoran LM, et al. Identification of Pax5 target genes in early B cell differentiation. J Immunol. 2008;180:1719–28.
pubmed: 18209069
doi: 10.4049/jimmunol.180.3.1719
Abdelrasoul H, Werner M, Setz CS, Okkenhaug K, Jumaa H. PI3K induces B-cell development and regulates B cell identity. Sci Rep. 2018;8:1327
pubmed: 29358580
pmcid: 5778048
doi: 10.1038/s41598-018-19460-5
Györy I, Boller S, Nechanitzky R, Mandel E, Pott S, Liu E, et al. Transcription factor Ebf1 regulates differentiation stage-specific signaling, proliferation, and survival of B cells. Genes Dev. 2012;26:668.
pubmed: 22431510
pmcid: 3323878
doi: 10.1101/gad.187328.112
Dengler HS, Baracho GV, Omori SA, Bruckner S, Arden KC, Castrillon DH, et al. Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat Immunol. 2008;9:1388–98.
pubmed: 18978794
pmcid: 2679692
doi: 10.1038/ni.1667
Ma S, Pathak S, Mandal M, Trinh L, Clark MR, Lu R. Ikaros and aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression. Mol Cell Biol. 2010;30:4149–58.
pubmed: 20566697
pmcid: 2937562
doi: 10.1128/MCB.00224-10
Ramezani-Rad P, Chen C, Zhu Z, Rickert RC. Cyclin D3 governs clonal expansion of dark zone germinal center B cells. Cell Rep. 2020;33:108403. https://doi.org/10.1016/j.celrep.2020.108403 .
doi: 10.1016/j.celrep.2020.108403
pubmed: 33207194
pmcid: 7714654